These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3516953)

  • 1. Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer.
    van den Bogaert W; van der Schueren E; Horiot JC; Chaplain G; Devilhena M; Raposo S; Leonor J; Schraub S; Chenal C; Barthelme E
    Int J Radiat Oncol Biol Phys; 1986 Apr; 12(4):587-91. PubMed ID: 3516953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group.
    Van den Bogaert W; van der Schueren E; Van Tongelen C; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
    Radiother Oncol; 1985 Feb; 3(2):139-44. PubMed ID: 3983422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of Cancer).
    Van den Bogaert W; van der Schueren E; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
    Int J Radiat Oncol Biol Phys; 1982 Oct; 8(10):1649-55. PubMed ID: 7153077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
    Van den Bogaert W; van der Schueren E; Horiot JC; De Vilhena M; Schraub S; Svoboda V; Arcangeli G; de Pauw M; Van Glabbeke M
    Radiother Oncol; 1995 May; 35(2):91-9. PubMed ID: 7569030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.
    Van den Bogaert W; van der Schueren E; Horiot JC; De Vilhena M; Schraub S; Svoboda V; Arcangeli G; de Pauw M; van Glabbeke M
    Radiother Oncol; 1995 May; 35(2):100-6. PubMed ID: 7569017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.
    Fazekas J; Pajak TF; Wasserman T; Marcial V; Davis L; Kramer S; Rotman M; Stetz J
    Int J Radiat Oncol Biol Phys; 1987 Aug; 13(8):1155-60. PubMed ID: 3301758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck.
    Panis X; Nguyen TD; Froissart D; Demange L
    Int J Radiat Oncol Biol Phys; 1984 Oct; 10(10):1845-9. PubMed ID: 6386760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of head and neck cancer. MRC working party on misonidazole in head and neck cancer.
    Br J Radiol; 1984 Jul; 57(679):585-95. PubMed ID: 6329395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).
    Lee DJ; Pajak TF; Stetz J; Order SE; Weissberg JB; Fischer JJ
    Int J Radiat Oncol Biol Phys; 1989 Feb; 16(2):465-70. PubMed ID: 2646255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer.
    Sealy R; Cridland S; Barry L; Norris R
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1343-6. PubMed ID: 3531113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of locally advanced head and neck cancer with misonidazole, hyperbaric oxygen and irradiation: an interim report.
    Sealy R; Cridland S
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1721-3. PubMed ID: 6384161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of misonidazole in association with a three-fractions per day regimen in advanced head and neck epidermoid cancer. A pilot study.
    Awwad HK; Barsoum M; El Merzabani M; Omar S; El Badawy S; Ezzat S; El Baki HA; Zaki A
    Am J Clin Oncol; 1983 Feb; 6(1):91-7. PubMed ID: 6301258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial.
    Simpson JR; Bauer M; Perez CA; Wasserman TH; Emami B; Doggett RL; Byhardt RW; Phillips TL; Mowry PA
    Int J Radiat Oncol Biol Phys; 1989 Jun; 16(6):1483-91. PubMed ID: 2542197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A report on misonidazole in randomized trial in locally advanced head and neck cancer.
    Sealy R; Williams A; Cridland S; Stratford M; Minchinton A; Hallet C
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):339-42. PubMed ID: 7050035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
    Rischin D; Peters L; Hicks R; Hughes P; Fisher R; Hart R; Sexton M; D'Costa I; von Roemeling R
    J Clin Oncol; 2001 Jan; 19(2):535-42. PubMed ID: 11208848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
    Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
    J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of the Scandinavian Glioblastoma Study Group.
    Hatlevoll R; Lindegaard KF; Hagen S; Kristiansen K; Nesbakken R; Torvik A; Ganz JC; Mella O; Rosengren B; Ringkjöb R
    Cancer; 1985 Jul; 56(1):41-7. PubMed ID: 2988737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer.
    Wanebo HJ; Glicksman AS; Landman C; Slotman G; Doolittle C; Clark J; Koness RJ
    Am J Surg; 1995 Nov; 170(5):512-6. PubMed ID: 7485745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.